Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (88)	6/11/2001 10:44:50 AM
From: tuck	Read Replies (2) \| Respond to of 1005

Wilder, Haven't looked at GNVC much yet. This brings them pretty close to book (per Yahoo!, unchecked), but still 2x cash. research premium about $20 million now. Everybody hates gene therapy these days, arouses the contrarian in me. biz.yahoo.com Lessee, chardonnays for celebrating the success of little chemistry companies such as AGNT or MCLS . . . If you traded a small position in one: ~$5: Baccala '99 If you traded a small position in both: ~$10: Hess Select '99; Buehler '99; Flora Springs '99 If you traded a medium position in both: ~$20: Talley '99 Arroyo Grande Valley And if you bet the farm, why screw around, cash some in now and get some Dom P. Favor the reds? For a change, try the Katnook Estate Riddoch '98 Coonawarra Cab/Shiraz. Those Aussies are getting good. ~$15 if you can get it. I'm currently drinking the Baccala (well not for breakfast; I have standards, you know). Cheers, Tuck